Search results
Abortion pill’s hazy legal future
Politico· 20 hours agoIT’S FRIDAY. WELCOME BACK TO PRESCRIPTION PULSE. Did you partake in the annual ice cream party on the Hill this week? We won’t judge...the discussions between the company ...
US charges executives at ADHD startup in $100 million Adderall fraud
FOX Business· 17 hours agoThe founder and the top doctor of a San Francisco-based telehealth startup were charged by the U.S....
Added health benefits of Wegovy, Zepbound could attract more men, doctors say
Reuters via Yahoo News· 5 days agoEvidence that weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound can cut heart...
Hims vs. Keeps: Which Hair Growth Subscription Service is Right for You?
Men's Journal· 4 days agoKeeps and Hims are two popular telehealth companies that offer hair loss treatments for men. There...
...Mysterious Stomach Issues as Best Friend Gayle King Reveals Shocking Symptoms That Has Fans...
Atlanta Black Star· 4 days agoMedia maven Oprah Winfrey has reportedly been hospitalized due to a mysterious “stomach issues,” according to her best friend Gayle King, who shared the news about her health status with the ...
Added health benefits of Wegovy, Zepbound could attract more men, doctors say By Reuters
Investing.com· 5 days agoMen prefer to shed extra pounds with diet and exercise changes before reaching for drugs, if they...
Feds arrest Adderall telehealth CEO under Controlled Substances Act
The Verge· 2 days agoRuthia He, the founder and CEO of the subscription-based “digital health company” Done, and the...
Focus: Added health benefits of Wegovy, Zepbound could attract more men, doctors say
Reuters· 5 days ago, opens new tab Zepbound can cut heart disease risk, treat sleep apnea and address other health...
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients...
Morningstar· 7 days agoEli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 7 days agoEli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide ...
